Thierry Andre News Today

Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.

Nivolumab/ipilimumab led to improvement in untreated MSI-H/dMMR disease versus chemo

First presentation of data from the Phase 3 randomized trial shows statistically significant and clinically meaningful improvement in progression-free survival with Opdivo plus Yervoy compared to...

Nivolumab/ipilimumab reduced the risk of disease progression or death vs chemotherapy in previously untreated patients with metastatic colorectal cancer.

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Calls to Mr. Roger often traced back to a simple cocktail party question: Where’d you get that dress?

Thierry Andre, MD, discusses negative overall survival results and updated safety data from the phase 3 SOLSTICE trial in metastatic colorectal cancer.

In a small study, just over half (59%) of patients who had combination immunotherapy showed no sign of tumor on preoperative endoscopy.

Neoadjuvant treatment with checkpoint inhibitors, followed by surgery and adjuvant immunotherapy, appears effective in MSI/dMMR gastric/GEJ cancer.